货号：GS40012
Adecatumumab is a recombinant, fully human IgG1 monoclonal antibody that targets the Epithelial Cell Adhesion Molecule (EpCAM). It was developed as an anti-cancer therapeutic, primarily for EpCAM-positive solid tumors such as prostate and breast cancer. Its proposed mechanism of action is two-fold: direct inhibition of tumor cell signaling and proliferation via EpCAM blockade, and induction of antibody-dependent cellular cytotoxicity (ADCC) to recruit immune cells for tumor cell killing. Clinical development advanced to Phase II trials, but further progression was discontinued.
武汉迈思生物科技有限公司
联系商家时请提及chemicalbook，有助于交易顺利完成！